Evidence map›Paper›PMID 39062028›Full record

ReviewBiomedicines2024

Insights into Personalized Care Strategies for Wilms Tumor: A Narrative Literature Review.

Salma Karam, Ahmad Gebreil, Ahmed Alksas, Hossam Magdy Balaha, Ashraf Khalil, Mohammed Ghazal, Sohail Contractor, Ayman El-Baz

Abstract readReview
In one paragraph

Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Exploring theFrontiers in physiology · 2025
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Salma KaramBioengineering Department, University of Louisville, Louisville, KY 40292, USA.
Ahmad GebreilBioengineering Department, University of Louisville, Louisville, KY 40292, USA.
Ahmed AlksasBioengineering Department, University of Louisville, Louisville, KY 40292, USA.ORCID 0000-0001-9409-931X
Hossam Magdy BalahaBioengineering Department, University of Louisville, Louisville, KY 40292, USA.
Ashraf KhalilCollege of Technological Innovation, Zayed University, Abu Dhabi 4783, United Arab Emirates.ORCID 0000-0003-1584-8525
Mohammed GhazalElectrical, Computer, and Biomedical Engineering Department, Abu Dhabi University, Abu Dhabi 59911, United Arab Emirates.ORCID 0000-0002-9045-6698
Sohail ContractorDepartment of Radiology, University of Louisville, Louisville, KY 40202, USA.
Ayman El-BazBioengineering Department, University of Louisville, Louisville, KY 40292, USA.ORCID 0000-0001-7264-1323

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wilms tumor (WT), or nephroblastoma, is the predominant renal malignancy in the pediatric population. This narrative review explores the evolution of personalized care strategies for WT, synthesizing critical developments in molecular diagnostics and treatment approaches to enhance patient-specific outcomes. We surveyed recent literature from the last five years, focusing on high-impact research across major databases such as PubMed, Scopus, and Web of Science. Diagnostic advancements, including liquid biopsies and diffusion-weighted MRI, have improved early detection precision. The prognostic significance of genetic markers, particularly WT1 mutations and miRNA profiles, is discussed. Novel predictive tools integrating genetic and clinical data to anticipate disease trajectory and therapy response are explored. Progressive treatment strategies, particularly immunotherapy and targeted agents such as HIF-2α inhibitors and GD2-targeted immunotherapy, are highlighted for their role in personalized treatment protocols, especially for refractory or recurrent WT. This review underscores the necessity for personalized management supported by genetic insights, with improved survival rates for localized disease exceeding 90%. However, knowledge gaps persist in therapies for high-risk patients and strategies to reduce long-term treatment-related morbidity. In conclusion, this narrative review highlights the need for ongoing research, particularly on the long-term outcomes of emerging therapies and integrating multi-omic data to inform clinical decision-making, paving the way for more individualized treatment pathways.

Indexed as

chemotherapygenetic profilingimmunotherapypediatric oncologypersonalized medicineradiation therapytargeted therapyWilms tumor

Identifiers

PMID39062028
PMCPMC11274555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.